{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:16:45Z","timestamp":1792811805146,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety profile of oral Janus kinase (JAK) inhibitors for treating alopecia areata (AA) among adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was conducted up to July 2025 across PubMed, Cochrane Library, Embase, and Web of Science for randomized controlled trials (RCTs) on oral JAK inhibitors in managing AA. Two qualified investigators conducted a separate review of the studies, evaluated their quality, and gathered pertinent information. R was utilized for all statistical evaluations, while the \u201cGeMTC\u201d package facilitated the Bayesian network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this analysis, 12 studies encompassing 3,840 individuals were examined. The findings from the network meta-analysis suggested that oral JAK inhibitors were generally safe for managing AA. Nonetheless, Baricitinib was linked to an increased likelihood of developing acne (RR [95% CrI] = 4.66 [2.00, 13.44]), urinary tract infections (RR [95% CrI] = 2.72 [1.14, 8.44]), and hyperlipidemia (RR [95% CrI] = 1.77 [1.44, 2.20]). Deuruxolitinib was tied to an increased probability of acne occurrence (RR [95% CrI] = 2.74 [1.58, 5.29]) and elevated creatine phosphokinase (CPK) levels (RR [95% CrI] = 1.98 [1.11, 3.93]). Similarly, ritlecitinib was connected to a greater likelihood of elevated CPK levels (RR [95% CrI] = 2.31 [1.01, 6.70]). The experimental data, which included different dose groups, were further analyzed through subgroup analysis. The results indicated that Baricitinib and Deuruxolitinib exhibited dose-dependent differences in the occurrence of acne and elevated CPK levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral JAK inhibitors exhibit a favorable safety profile for the treatment of AA. However, baricitinib is more likely to cause acne and infections as opposed to other agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1576553","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:24:17Z","timestamp":1754889857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ziyu","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"B1","unstructured":"Ema starts safety review of janus kinase inhibitors for inflammatory disorders\n          \n          \n            \n              Agency\n              E. M.\n            \n          \n          \n          2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2147\/dddt.S109287","article-title":"Sitagliptin attenuates cardiomyopathy by modulating the jak\/stat signaling pathway in experimental diabetic rats","volume":"10","author":"Al-Rasheed","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1002\/prp2.1204","article-title":"A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata","volume":"12","author":"Anderson","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e14563","DOI":"10.1111\/dth.14563","article-title":"Activation of janus kinase signaling pathway in acne lesions","volume":"34","author":"Awad","year":"2021","journal-title":"Dermatol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2397477","DOI":"10.1080\/09546634.2024.2397477","article-title":"Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis","volume":"35","author":"Chen","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"B7","unstructured":"Study to evaluate the efficacy and safety of Ctp-543 in adults with moderate to severe alopecia Areata(Thrive-Aa2)(Thrive-Aa2)\n          \n          \n          2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s13555-024-01208-x","article-title":"Improvement in measures of quality of life and symptoms of anxiety and depression in patients with severe alopecia areata achieving sustained scalp hair regrowth with baricitinib","volume":"14","author":"Craiglow","year":"2024","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/1346-8138.17064","article-title":"Alopecia areata: what's new in the diagnosis and treatment with jak inhibitors?","volume":"51","author":"Dainichi","year":"2024","journal-title":"J. Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00403-024-03177-9","article-title":"Comparative efficacy and safety of systemic steroids, oral jak inhibitors and contact immunotherapy in the treatment of severe alopecia areata: a systematic review and network meta-analysis","volume":"316","author":"Guan","year":"2024","journal-title":"Arch. Dermatol Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jdin.2024.09.012","article-title":"Risk of infections during treatment with oral janus kinase inhibitors in randomized placebo-controlled trials: a systematic review and meta-analysis","volume":"18","author":"Isufi","year":"2025","journal-title":"JAAD Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of Ctp-543, a selective janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/s0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (Thrive-Aa1)","volume":"91","author":"King","year":"2024","journal-title":"J. Am. Acad. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","article-title":"Biologics versus jak inhibitors. Part ii: risk of infections. A narrative review","volume":"14","author":"Mansilla-Polo","year":"2024","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s13555-023-01067-y","article-title":"Degree of alignment between Japanese patients and physicians on alopecia areata disease severity and treatment satisfaction: a real-world survey","volume":"14","author":"Nakamura","year":"2024","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"Jak and stat signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40261-023-01260-z","article-title":"Safety of janus kinase inhibitors in patients with alopecia areata: a systematic review","volume":"43","author":"Papierzewska","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00403-024-03203-w","article-title":"Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial","volume":"316","author":"Paracha","year":"2024","journal-title":"Arch. Dermatol Res."},{"key":"B24","unstructured":"Phase 3b\/4 randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor (tnf) inhibitor in subjects with rheumatoid arthritis\n          \n          \n            \n              Register\n              E. C. T.\n            \n          \n          \n          2021"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/j.1348-0421.2000.tb02599.x","article-title":"Il-12, ifn-gamma, and tnf-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella","volume":"44","author":"Torigo","year":"2000","journal-title":"Microbiol. Immunol."},{"key":"B26","unstructured":"Fda requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for jak inhibitors that treat certain chronic inflammatory conditions\n          \n          \n            \n              UsfaD\n              A.\n            \n          \n          \n          2021"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12423","DOI":"10.1073\/pnas.0806372105","article-title":"In vivo studies fail to reveal a role for Il-4 or Stat6 signaling in Th2 lymphocyte differentiation","volume":"105","author":"van Panhuys","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s13555-024-01133-z","article-title":"Characteristics and management of patients with alopecia areata and selected comorbid conditions: results from a survey in five European countries","volume":"14","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2024","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by jak inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2455536","DOI":"10.1080\/07853890.2025.2455536","article-title":"Cardiovascular safety of janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis","volume":"57","author":"Yang","year":"2025","journal-title":"Ann. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase Ii study to evaluate the efficacy and safety of ivarmacitinib (Shr0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J. Am. Acad. Dermatol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1576553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:24:19Z","timestamp":1754889859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1576553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1576553"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1576553","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"article-number":"1576553"}}